Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma–supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes. Significance: Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.
Introduction: Orthopaedic surgery is one of the most competitive specialties. In 2024, 1,492 medical students applied to 916 orthopaedic surgery first-year training positions. There are no recent data examining trends in the number of away rotations performed by medical students interested in orthopaedic surgery. The purpose of this study was to enhance understanding about the significance of away rotations and home rotations for successfully matching into orthopaedic surgery. Methods: In January 2024, the survey was distributed to orthopaedic surgery postgraduate year 1 (PGY-1) students at programs participating in the Collaborative Orthopaedic Education Research Group (COERG). The survey was distributed in March 2024 to 4th-year medical students who rotated at participating COERG residency programs. Data were collected on away rotations completed, motivations for participating, barriers encountered, and if the respondent matched at a program where they rotated. Results: Survey responses were collected from 37 of 90 PGY-1 students (41.1%) and 62 of 325 4th-year medical students (19.1%). The study cohort consisted of 99 applicants from the 2023 and 2024 orthopaedic surgery residency match cycles. PGY-1 students and 4th-year medical students completed an average of 3.4 away rotations and applied to an average of 4.4. Eight of 62 4th-year medical students (12.9%) did not match, with their average number of away rotations being 3.75. Of the 91 respondents who matched, 50 (54.9%) matched at an outside program where they rotated during 4th year. Fifteen (16.5%) matched at their home program. Fifteen (16.5%) matched at a program they had no prior exposure to before the residency interview. Six (6.6%) matched at a program with prior exposure and no away rotation. Five (5.5%) matched at a program with geographical ties and no away rotation. Conclusion: Medical students applying to orthopaedic surgery residency are completing more away rotations than noted in previous studies. Most medical students match at programs where they complete away rotations or their home program, which subsequently increases the importance of where students decide to do rotations and the number they complete.
Bone marrow vascular endothelial cells (BM EC) regulate multiple myeloma pathogenesis. Identification of the mechanisms underlying this interaction could lead to the development of improved strategies for treating multiple myeloma. Here, we performed a transcriptomic analysis of human ECs with high capacity to promote multiple myeloma growth, revealing overexpression of the receptor tyrosine kinases, EPHB1 and EPHB4, in multiple myeloma–supportive ECs. Expression of ephrin B2 (EFNB2), the binding partner for EPHB1 and EPHB4, was significantly increased in multiple myeloma cells. Silencing EPHB1 or EPHB4 in ECs suppressed multiple myeloma growth in coculture. Similarly, loss of EFNB2 in multiple myeloma cells blocked multiple myeloma proliferation and survival in vitro, abrogated multiple myeloma engraftment in immune-deficient mice, and increased multiple myeloma sensitivity to chemotherapy. Administration of an EFNB2-targeted single-chain variable fragment also suppressed multiple myeloma growth in vivo. In contrast, overexpression of EFNB2 in multiple myeloma cells increased STAT5 activation, increased multiple myeloma cell survival and proliferation, and decreased multiple myeloma sensitivity to chemotherapy. Conversely, expression of mutant EFNB2 lacking reverse signaling capacity in multiple myeloma cells increased multiple myeloma cell death and sensitivity to chemotherapy and abolished multiple myeloma growth in vivo. Complementary analysis of multiple myeloma patient data revealed that increased EFNB2 expression is associated with adverse-risk disease and decreased survival. This study suggests that EFNB2 reverse signaling controls multiple myeloma pathogenesis and can be therapeutically targeted to improve multiple myeloma outcomes.Significance:Ephrin B2 reverse signaling mediated by endothelial cells directly regulates multiple myeloma progression and treatment resistance, which can be overcome through targeted inhibition of ephrin B2 to abolish myeloma.